Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma

Lin,Cheng-Wei; Sun,Min-Siou; Wu,Han-Chung

doi:10.3892/ijo.2014.2427

Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma

Authors:
- Cheng-Wei Lin
- Min-Siou Sun
- Han-Chung Wu
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Taipei Medical University, Taipei 115, Taiwan, R.O.C., Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 115, Taiwan, R.O.C.
Published online on: May 8, 2014 https://doi.org/10.3892/ijo.2014.2427
Pages: 710-718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis-mediated death remains a major challenge in cancer treatment due to the lack of identifiable biomarkers for early diagnosis. Identifying tumor-specific biomarkers is critical for the development of diagnostic and therapeutic tools. In the present study, we found that podocalyxin-like 1 (PODXL), a cell surface glycoprotein, was overexpressed in cancer tissues and was upregulated in lymph node metastatic tumor cells. The expression of PODXL was associated with the migratory ability of human oral squamous cell carcinoma (OSCC). Knockdown of PODXL by small hairpin RNA in the SAS OSCC cell line reduced tumor migration and invasion, and inhibited cell proliferation and colony formation. Suppression of PODXL resulted in downregulation of focal adhesion kinase (FAK) and paxillin phosphorylation. PODXL silencing inhibited filopodia formation, and suppressed F-actin and cortactin colocalization. In addition, PODXL expression was associated with the DNA methylation status, and treatment with the DNA methyltransferase inhibitor 5-aza-deoxycytidine increased the PODXL transcriptional level. Moreover, DNA microarray analysis data revealed that suppression of PODXL significantly affected subsets of genes associated with extracellular matrix organization, the epithelial-mesenchymal transition, and the expression of metastasis-related cytokines. Collectively, these data showed that the overexpression of PODXL may be associated with tumor aggressiveness and that PODXL could be a diagnostic biomarker for metastatic OSCC.

View Figures

View References

1	Chen YJ, Chang JT, Liao CT, et al: Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 99:1507–1514. 2008. View Article : Google Scholar : PubMed/NCBI
2	Zygogianni AG, Kyrgias G, Karakitsos P, et al: Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 3:22011. View Article : Google Scholar : PubMed/NCBI
3	Fina L, Molgaard HV, Robertson D, et al: Expression of the CD34 gene in vascular endothelial cells. Blood. 75:2417–2426. 1990.PubMed/NCBI
4	Labastie MC, Cortes F, Romeo PH, Dulac C and Peault B: Molecular identity of hematopoietic precursor cells emerging in the human embryo. Blood. 92:3624–3635. 1998.PubMed/NCBI
5	Kerjaschki D, Sharkey DJ and Farquhar MG: Identification and characterization of podocalyxin - the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol. 98:1591–1596. 1984. View Article : Google Scholar : PubMed/NCBI
6	Doyonnas R, Nielsen JS, Chelliah S, et al: Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood. 105:4170–4178. 2005. View Article : Google Scholar : PubMed/NCBI
7	Nielsen JS and McNagny KM: The role of podocalyxin in health and disease. J Am Soc Nephrol. 20:1669–1676. 2009. View Article : Google Scholar : PubMed/NCBI
8	Economou CG, Kitsiou PV, Tzinia AK, et al: Enhanced podocalyxin expression alters the structure of podocyte basal surface. J Cell Sci. 117:3281–3294. 2004. View Article : Google Scholar : PubMed/NCBI
9	Sizemore S, Cicek M, Sizemore N, Ng KP and Casey G: Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 67:6183–6191. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hsu YH, Lin WL, Hou YT, et al: Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol. 176:3050–3061. 2010. View Article : Google Scholar
11	Schmieder S, Nagai M, Orlando RA, Takeda T and Farquhar MG: Podocalyxin activates RhoA and induces actin reorganization through NHERF1 and Ezrin in MDCK cells. J Am Soc Nephrol. 15:2289–2298. 2004. View Article : Google Scholar : PubMed/NCBI
12	Doyonnas R, Kershaw DB, Duhme C, et al: Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med. 194:13–27. 2001. View Article : Google Scholar : PubMed/NCBI
13	Forse CL, Yilmaz YE, Pinnaduwage D, et al: Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer. Breast Cancer Res Treat. 137:709–719. 2013. View Article : Google Scholar
14	Binder ZA, Siu IM, Eberhart CG, et al: Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome. PLoS One. 8:e759452013. View Article : Google Scholar : PubMed/NCBI
15	Boman K, Larsson AH, Segersten U, et al: Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer. 108:2321–2328. 2013. View Article : Google Scholar : PubMed/NCBI
16	Larsson A, Johansson ME, Wangefjord S, et al: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer. 105:666–672. 2011. View Article : Google Scholar : PubMed/NCBI
17	Chen QW, Zhu XY, Li YY and Meng ZQ: Epigenetic regulation and cancer (Review). Oncol Rep. 31:523–532. 2014.
18	Jithesh PV, Risk JM, Schache AG, et al: The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer. 108:370–379. 2013. View Article : Google Scholar : PubMed/NCBI
19	Huang TT, Gonzales CB, Gu F, et al: Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis. 34:1717–1727. 2013. View Article : Google Scholar : PubMed/NCBI
20	Towle R, Truong D, Hogg K, Robinson WP, Poh CF and Garnis C: Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol. 49:1033–1042. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hong Y, Downey T, Eu KW, Koh PK and Cheah PY: A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 27:83–90. 2010.
22	Kaiser S, Park YK, Franklin JL, et al: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 8:R1312007. View Article : Google Scholar : PubMed/NCBI
23	Ki DH, Jeung HC, Park CH, et al: Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer. 121:2005–2012. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sabates-Bellver J, Van der Flier LG, de Palo M, et al: Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 5:1263–1275. 2007. View Article : Google Scholar
25	Skrzypczak M, Goryca K, Rubel T, et al: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One. 5:pii: e13091. 2010. View Article : Google Scholar : PubMed/NCBI
26	Cho JY, Lim JY, Cheong JH, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 17:1850–1857. 2011. View Article : Google Scholar : PubMed/NCBI
27	D’Errico M, de Rinaldis E, Blasi MF, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer. 45:461–469. 2009.PubMed/NCBI
28	Wang Q, Wen YG, Li DP, et al: Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 29:77–83. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chen X, Cheung ST, So S, et al: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar PubMed/NCBI
30	Mas VR, Maluf DG, Archer KJ, et al: Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 15:85–94. 2009.PubMed/NCBI
31	Roessler S, Jia HL, Budhu A, et al: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar
32	Wurmbach E, Chen YB, Khitrov G, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
33	Su H, Hu N, Yang HH, et al: Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin Cancer Res. 17:2955–2966. 2011. View Article : Google Scholar : PubMed/NCBI
34	Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB and Lowe AW: Gene expression profiling reveals stromal genes expressed in common between Barrett’s esophagus and adenocarcinoma. Gastroenterology. 131:925–933. 2006.PubMed/NCBI
35	Hu N, Clifford RJ, Yang HH, et al: Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics. 11:5762010. View Article : Google Scholar : PubMed/NCBI
36	Kim SM, Park YY, Park ES, et al: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 5:e150742010. View Article : Google Scholar : PubMed/NCBI
37	Kimchi ET, Posner MC, Park JO, et al: Progression of Barrett’s metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 65:3146–3154. 2005.
38	Cromer A, Carles A, Millon R, et al: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 23:2484–2498. 2004. View Article : Google Scholar : PubMed/NCBI
39	Ginos MA, Page GP, Michalowicz BS, et al: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64:55–63. 2004. View Article : Google Scholar : PubMed/NCBI
40	Schlingemann J, Habtemichael N, Ittrich C, et al: Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. Lab Invest. 85:1024–1039. 2005. View Article : Google Scholar : PubMed/NCBI
41	Sengupta S, den Boon JA, Chen IH, et al: Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 66:7999–8006. 2006. View Article : Google Scholar : PubMed/NCBI
42	Toruner GA, Ulger C, Alkan M, et al: Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet. 154:27–35. 2004. View Article : Google Scholar : PubMed/NCBI
43	Murphy DA and Courtneidge SA: The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 12:413–426. 2011.
44	Sung BH, Zhu X, Kaverina I and Weaver AM: Cortactin controls cell motility and lamellipodial dynamics by regulating ECM secretion. Curr Biol. 21:1460–1469. 2011. View Article : Google Scholar : PubMed/NCBI
45	Oser M, Yamaguchi H, Mader CC, et al: Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol. 186:571–587. 2009. View Article : Google Scholar : PubMed/NCBI
46	Clark ES, Whigham AS, Yarbrough WG and Weaver AM: Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 67:4227–4235. 2007. View Article : Google Scholar : PubMed/NCBI
47	Dallas MR, Chen SH, Streppel MM, Sharma S, Maitra A and Konstantopoulos K: Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells. Am J Physiol Cell Physiol. 303:C616–C624. 2012. View Article : Google Scholar : PubMed/NCBI
48	Thomas SN, Schnaar RL and Konstantopoulos K: Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol. 296:C505–C513. 2009. View Article : Google Scholar
49	Su PF, Huang WL, Wu HT, Wu CH, Liu TY and Kao SY: p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner. Oral Oncol. 46:734–739. 2010. View Article : Google Scholar : PubMed/NCBI
50	Alyasiri NS, Ali A, Kazim Z, et al: Aberrant promoter methylation of PTEN gene among Indian patients with oral squamous cell carcinoma. Int J Biol Markers. 28:298–302. 2013. View Article : Google Scholar : PubMed/NCBI
51	Viswanathan M, Tsuchida N and Shanmugam G: Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer. 105:41–46. 2003. View Article : Google Scholar : PubMed/NCBI
52	Butta N, Larrucea S, Alonso S, et al: Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Mol Biol. 7:172006. View Article : Google Scholar : PubMed/NCBI
53	Cao YX, Jean JC and Williams MC: Cytosine methylation of an Sp1 site contributes to organ-specific and cell-specific regulation of expression of the lung epithelial gene t1alpha. Biochem J. 350:883–890. 2000. View Article : Google Scholar : PubMed/NCBI